pharma
dog
News
when
Latest
Archive
by source
All Sources
Sources Page
Jobs
department
Clinical
Regulatory
Medical Affairs
Commercial
R&D / Discovery
Biostatistics / Data
Manufacturing / CMC
Market Access
therapeutic area
Oncology
Immunology
Neuroscience
Cardiovascular
Metabolic
Rare Disease
Infectious Disease
location & type
Remote Only
US Only
California
Massachusetts
Internships
Phase 3 Roles
All Jobs →
Drugs
by stage
Marketed
Phase 3
Phase 2
Phase 1
Preclinical
browse
Most catalysts
Recently active
All drugs →
Companies
Patent cliff
Calendar
what
Trial readouts
PDUFA dates
Approvals
Earnings
when
Upcoming
Month grid
Recently passed
◐
Sign In
Subscribe
home
jobs
news
search
Spravato · news · pharmadog
← back to Spravato
News mentioning Spravato
13
stories
14d
How J&J paved the way for Compass’ coming psychedelic drug launch
biopharma dive
19d
Deep dive: Psychedelics back on FDA’s doorstep
biospace
20d
Stakeholders urge FDA to define data, treatment standards as psychedelic drugs near market
biospace
21d
Psychedelic therapies ride wave of public favor into FDA hearing
biospace
Aug 10, 26
Psychedelics on the cusp of market breakthrough as clinical, policy support grow
biospace
Jul 24, 26
Lilly’s $3.8B psychedelics bet won’t open the M&A floodgates
biospace
Jul 20, 26
Lilly’s AtaiBeckley buy validates space as Big Pharma takes note of psychedelics
biospace
Jul 18, 26
‘A rising tide scenario’: Why other Big Pharmas could follow Lilly into psychedelics
fiercebiotech
Jul 16, 26
Lilly to buy AtaiBeckley for $2.8B, further validating psychedelics
biopharma dive
Jul 16, 26
Lilly makes up to $3.8B psychedelics play in AtaiBeckley takeover
biospace
Jul 16, 26
J&J sees Spravato sales surge as psychedelic competitors loom
biospace
Jul 15, 26
J&J dips despite upbeat outlook; AstraZeneca, Spero cut China deals
biopharma dive
Jul 8, 26
Another big premium hike on the horizon
stat
